Pfizer (NYSE:PFE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Pfizer Trading Down 1.7%

Shares of NYSE PFE traded down $0.46 during midday trading on Thursday, hitting $26.85. 38,500,025 shares of the company traded hands, compared to its average volume of 47,038,105. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.94. The stock has a 50-day moving average price of $26.43 and a 200 day moving average price of $25.50. The firm has a market cap of $152.65 billion, a P/E ratio of 19.74 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were given a dividend of $0.43 per share. The ex-dividend date was Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. Pfizer’s payout ratio is currently 126.47%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PFE shares. Morgan Stanley reduced their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price target for the company. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.05.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying for long‑term use in overweight/obese adults — expands commercialization opportunity in a large market and adds a new revenue stream. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Tilrekimig (trispecific antibody) Phase 2 data showed meaningful eczema improvements with a favorable safety profile — if confirmed in later trials this could materially strengthen Pfizer’s immunology franchise. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer launched an early‑stage cancer trial for PF‑07994525, extending its oncology pipeline and signaling continued R&D investment in high‑value therapeutics. Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline
• Positive Sentiment: Pfizer completed a Phase 2 toddler study for a next‑gen pneumococcal vaccine — progress in the vaccine franchise supports recurring revenue potential. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Market roundup pieces and industry commentary (Health Care Roundup) mention Pfizer among peers; useful context but no single headline-moving development. Health Care Roundup: Market Talk
• Neutral Sentiment: Pfizer’s regulatory team commentary on adapting to uncertainty is informative about process but not an immediate stock catalyst. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Coverage of a patent “shake‑up” around tafamidis and related moves (BridgeBio reaction) highlights IP/legal uncertainty that could threaten revenues for legacy drugs if exclusivity is weakened. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Negative Sentiment: Analyst/opinion pieces arguing “Pfizer: Cheap For A Reason” and valuation debates keep downward pressure from investors concerned about post‑pandemic sales slopes and patent cliffs. Pfizer: Cheap For A Reason

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently modified their holdings of the stock. Fiduciary Alliance LLC raised its holdings in shares of Pfizer by 46.4% during the third quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Pfizer in the third quarter worth approximately $3,019,000. Vista Investment Partners LLC grew its position in Pfizer by 236.1% in the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after purchasing an additional 48,900 shares during the period. Money Concepts Capital Corp raised its stake in Pfizer by 29.9% during the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after buying an additional 57,188 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. lifted its holdings in shares of Pfizer by 76.4% during the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after buying an additional 47,319 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.